Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect
- PMID: 9554747
- DOI: 10.1002/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S
Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect
Abstract
Glycogen storage disease type II (GSD II, Pompe's disease), an autosomal recessive inherited disease, is caused by the deficiency of acid alpha-D-glucosidase, which results in the impaired glycogen degradation in lysosome and causes excess glycogen accumulation in lysosome. In Taiwan, the infantile form of GSD II is the most common type of glycogen storage diseases. The frequency of C1935A mutant allele is 0.8 in these Chinese patients. In this study, we analyzed four single point polymorphic markers (324, 1203, 2065, 2338) by ACRS-based RFLP We observed that the alleles possessing the C1935A mutation in 19 of 25 Chinese patients who were heterozygous or homozygous have conserved polymorphic markers, and all of C1935A mutant alleles in these patients are linked to a specific haplotype. The allele frequency of this specific haplotype in 19 Chinese patients and in 42 normal individuals is 0.95 and 0.17, respectively (P<0.005, chi2 = 66.018). This result suggests that the C1935A mutation in Chinese patients with infantile form of GSD II is due to the founder effect.
Similar articles
-
Identification of a small deletion in one allele of patients with infantile form of glycogen storage disease type II.Biochem Biophys Res Commun. 1996 Feb 15;219(2):322-6. doi: 10.1006/bbrc.1996.0231. Biochem Biophys Res Commun. 1996. PMID: 8604985
-
Identification of a de novo point mutation resulting in infantile form of Pompe's disease.Biochem Biophys Res Commun. 1995 Mar 17;208(2):886-93. doi: 10.1006/bbrc.1995.1418. Biochem Biophys Res Commun. 1995. PMID: 7695647
-
Glycogen-storage disease type II (acid maltase deficiency): identification of a novel small deletion (delCC482+483) in French patients.Biochem Biophys Res Commun. 1997 Jun 9;235(1):138-41. doi: 10.1006/bbrc.1997.6749. Biochem Biophys Res Commun. 1997. PMID: 9196050
-
[Pompe's disease--acid alpha-glucosidase deficiency--a review].Nihon Rinsho. 1993 Sep;51(9):2324-9. Nihon Rinsho. 1993. PMID: 8411709 Review. Japanese.
-
[Pompe's disease. Part I: pathogenesis and clinical features].Ideggyogy Sz. 2009 Jul 30;62(7-8):231-43. Ideggyogy Sz. 2009. PMID: 19685701 Review. Hungarian.
Cited by
-
Pompe Disease: From Basic Science to Therapy.Neurotherapeutics. 2018 Oct;15(4):928-942. doi: 10.1007/s13311-018-0655-y. Neurotherapeutics. 2018. PMID: 30117059 Free PMC article. Review.
-
Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase".J Hum Genet. 2007;52(11):898-906. doi: 10.1007/s10038-007-0191-9. Epub 2007 Sep 6. J Hum Genet. 2007. PMID: 17805474
-
A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.Iran J Med Sci. 2018 Mar;43(2):218-222. Iran J Med Sci. 2018. PMID: 29749992 Free PMC article.
-
Infantile Pompe disease: A case report and review of the Chinese literature.Exp Ther Med. 2016 Jan;11(1):235-238. doi: 10.3892/etm.2015.2862. Epub 2015 Nov 12. Exp Ther Med. 2016. PMID: 26889246 Free PMC article.
-
CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C>A (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease.Sci Rep. 2022 Dec 14;12(1):21576. doi: 10.1038/s41598-022-25914-8. Sci Rep. 2022. PMID: 36517654 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources